lates, at least in part, with specific FAC mutations." The human FAC gene is composed of 14 exons that encode its protein seq~ence.'~ In general, mild disease appears to result from mutations in exon 1, and severe disease results from mutations in exons 4, 6, or 14. The molecular basis for this clinical variability among group C FA patients is unknown.
lates, at least in part, with specific FAC mutations." The human FAC gene is composed of 14 exons that encode its protein seq~ence.'~ In general, mild disease appears to result from mutations in exon 1, and severe disease results from mutations in exons 4, 6, or 14. The molecular basis for this clinical variability among group C FA patients is unknown.
We reasoned that the mild form of FA(C) (exon 1 mutation) could be accounted for by the expression of specific isoforms of the FAC polypeptide that retain partial function. To test this hypothesis, we analyzed FAC polypeptides expressed in cells derived from patients with either mild or severe disease. Cells derived from group C patients with mild disease, but not severe disease, expressed a truncated FAC polypeptide (FRP-50), resulting from loss of the normal amino terminus of FAC. FRP-50 was also expressed in cells derived from normal controls. Moreover, the ectopic expression of FRP-50 in an MMC-sensitive FA(C) cell line conferred partial MMC resistance. These findings demonstrate that the carboxy portion of the FAC polypeptide is required for its cellular function and that internal translation initiation of the FAC polypeptide can account, at least in part, for the clinical heterogeneity among some patients with group C FA.
MATERIALS AND METHODS
Cell lines and culture conditions. Epstein-Barr virus (EBV)-transformed normal and mutant FA lymphoblast lines have been previously described.'.'' Cells were maintained as suspension cultures in RPMI media supplemented with 15% heat-inactivated fetal calf serum (FCS). They were grown at 37°C in a humidified, 5% C0,-containing atmosphere.
A polyclonal antiserum against the carboxy terminus of FAC (amino acid 281-558) has previously been described." For affinity-purification, the 3' end of the FAC cDNA (amino acids 502-558) was subcloned into the pGEX2T vector (Pharmacia), maintaining the glutathione-s-transferase (GST) protein and FAC in frame. This GST fusion protein (GST-FAC-C 1) was synthesized and coupled to CNBr-activated Sepharose 4B via its primary amino group. The anti-FAC antiserum was first depleted of antibodies against GST by passage over a GSTSepharose 4B column. The flow-through was then applied to the GST-FAC-C1-Sepharose 4B column. After extensive washing with phosphate-buffered saline (PBS) (pH 7.4), the antibody against FAC-C1 (C1 antibody) was eluted from the GST-FAC-C1-Sepharose 4B column with 0.1 m o m glycine and 1 m o m acetic acid (pH 2.4). dialyzed against a large volume of PBS (pH 7.4), and concentrated Metabolic labeling of EBV-transformed lymphoblasts with "S-methionine (2 hours) and immunoprecipitation of labeled proteins were performed as described previously." Briefly, cell extracts in TBS (50 mmovL Trisbuffered isotonic saline, pH = 7.5) containing 5 mmom EDTA and 1% (voVvol) Triton X-100, 0.2% sodium dodecyl sulfate (SDS)
Metabolic labeling and immunoprecipitation.
were precleared with preimmune serum and mixed with C1 and C3 antibody (4 pg/mL). Protein A-sepharose (Pharmacia) immune complexes were washed three times with TBS containing 1% Triton X-100 and 0.1% SDS, and subjected to SDS-polyacrylamide gel electrophoresis (PAGE).
Statistical analysis. Statistical correlations were calculated using the Fischer's exact test in a two by two contingency table."
Transfection of FA lymphoblasts. FAC cDNAs encoding mutant forms of the FAC polypeptide were generated by polymerase chain reaction (PCR) and cloned into the KpnI and BamHI sites of the pREP4 expression vector (Invitrogen, San Diego, CA). All cDNAs were confirmed by sequencing. Plasmid DNA (10 pg) was transfected by lipofection into HSC536N cells (2.5 X 106 cells), as previously described.I6 Selection with hygromycin (0.1 mg/mL) in RPMI medium 1640 with 15% FCS was initiated 72 hours after transfection. Selected cells were analyzed for the presence of wild type or mutant polypeptides by immunoprecipitation. MMC sensitivity of the HSC536N transfectants was performed as previously described.I6
Transfected HSC536N cells (2.5 X lo6 cells) were grown in the absence or presence of mitomycin C (MMC) at 0.1 pmovL for 48 hours. Cells were washed once with PBS, resuspended in 0.5 mL of a solution containing 0.1% citrate, 0.03% NP-40, and 0.7 p m o m propidium iodide, and incubated at room temperature for 30 minutes. RNaseA (20 pg/mL) was added, and the incubation continued for another 30 minutes at 37°C. Approximately 10, OOO cells were analyzed for fluorescence intensity at an event rate of 2,500 by FACScan (Becton Dickinson). The percentage of cells in each phase of the cell cycle was determined by analysis with the computer program CellFIT (Becton Dickinson). Data shown is representative of at least three separate transfections.
Assay for correction of cell cycle arrest.
RESULTS

Mild group C FA correlates with the expression of an
Several specific mutations FAC-related Protein, FRP-50. n n n n n n have been identified within the FAC The most frequent mutations are the IVS4 + 4 A to T mutation, which results in the loss of exon 4" and the delG322 mutation, which results in a frameshift and a premature STOP codon in exon Together, these two mutations account for approximately 90% of known FA(C) mutations (Fig I) .
Initially, we compared the clinical severity of several FA patients by using the clinical score of Auerbach et al" (Table  I ). This score was originally described for distinguishing FA patients from non-FA patients with aplastic anemia and, more recently, was shown to be proportional to the severity of the FA phenotype." The score is calculated by adding one point each for growth retardation, birthmarks, kidney and urinary tract abnormalities, microophthalmia, low plate- lets, or thumb and radial abnormalities and by subtracting one point each for leaming disabilities and other skeletal abnormalities. The score thus ranges from -2 to +6; a score below 3 is defined as a mild phenotype. There is no evidence that the score is a useful predictor of bone marrow failure or cancer susceptibility.
Based on this clinical score, we compared the severity of patients with either the IVS4 + 4 A to T mutation or the delG322 mutation (Table I) . A mild FA clinical score (<3) correlated with the homozygous deIG322 genotype, while a severe FA clinical score (>3) correlated with the homozygous IVS4 + 4 A to T genotype ( P = .0008).
We next analyzed FAC polypeptides expressed in EBVtransformed lymphoblast lines derived from normal adult
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From (Fig 2B and 2C) . Cell lines from patients with delG322 did not express full length FAC, but did express FRP-SO (Fig 2B, lane 7 and Fig 2C, lanes 4, 6,   8 , and IO). Cell lines from patients with IVS4 + 4 A to T did not express full length FAC, but did express a 55-kD truncated protein (Fig 2B, lanes 3, S and Fig 2C, lane 12) , consistent with the in frame deletion of 37 amino acids from the FAC polypeptide." Table 1 To confirm that FRP-SO is derived from the FAC gene, we prepared two discrete antisera against FAC, directed against different linear epitopes (Fig 3) . Both C1 and C3 antisera immunoprecipitated FAC and FRP-SO (Fig 3, lanes 2 and 4,  respectively) , suggesting that these two proteins are highly related isoforms. In contrast, CI, but not C3, recognized an epitope of FRP-IS0 (lane 2 v lane 4). suggesting that FRP-1 SO and FAC are only related in the CI epitope. Immunoprecipitation of FAC and FRP-SO by CI antibody was competed by an excess of GST-FAC-CI (lane 3). but not by GST (data not shown). Immunoprecipitation of FAC and FRP-SO by C3 antibody was competed by GST-FAC, containing amino acids 281-558 of FAC (lane 5). but not by GST-FAC-CI (lane 6), confirming that CI and C3 antisera recognize nonoverlapping epitopes. FRP-SO from PD4 cells ( Table 1) also is recognized by the Cl and C3 antibody (data not shown). Taken together, these results demonstrate that FAC and FRP-SO share two discrete epitopes and that FRP-SO is probably encoded by the FAC gene.
FRP-50 is an isojbrm of the FAC polvpeptide, initiated inteninlls at methionine 55. Because FAC and FRPJO have related epitopes at the carboxy terminus, we reasoned that FRP-SO is an isoform of FAC that lacks the normal amino terminus encoded by exon I . To test this hypothesis, we generated mutant FAC cDNAs by in vitro mutagenesis (Fig 4) . These cDNAs encode FAC polypeptides with amino terminal truncations. The TI, T2, and T3 cDNAs encode FAC polypeptides that initiate at methionine 48 (M48), me- thionine 55 (M55), and methionine 350 (M350), respectively ( Fig 4A) . An MMC-sensitive, type C FA cell line, HSC536N, was transfected with the cDNAs encoding either full-length or truncated FAC polypeptides. Transfected cells were selected in hygromycin and assayed for the presence of the mutant polypeptides (Fig 4B and C) . Untransfected HSC536N cells expressed a mutant FAC polypeptide .(60 kD) and mutant FRP-50, (Fig 4B, lane 2) . as previously described.'" Both FAC and FRP-50 in these cells have an L554P missense mutation and have no functional activity." Cells transfected with full-length FAC cDNA had increased expression of both FAC and FRPJO (Fig 4B, lane 4 kD, 50 kD, and 25 kD, respectively (Fig 4B and C) . The T2 FAC polypeptide had the same electrophoretic mobility as FRPJO, suggesting that these polypeptides are identical. Consistent with these results, the in vitro transcription and translation of the full-length FAC cDNA resulted in synthesis of both FAC and FRP-50 (data not shown). (Fig 5) . FAC(L554P) mutant, or mock-transfected remained sensitive to Mh4C. Interestingly, overexpression of both the T1 and T2(FRP-50) mutant polypeptides resulted in partial correction of the MMC sensitivity of the FA(C) cell line.
HSC536N cells, transfected with the T3 mutant, an
To verify the partial functional activity of T2(FRP-50), we designed a second in vitro complementation assay (Fig  6) . This assay exploits the fact that FA cells, unlike normal cells, accumulate in the G2 phase of the cell cycle following low-dose exposure to MMC.1326,27 Control cells (HSC536N-mock) and cells transfected with wild-type FAC (HSC536N-wt FAC) showed a similar cell cycle distribution in the absence of MMC (Fig 6A and C) . After treatment with a low concentration of MMC (0.1 pmol/L) for 48 hours, HSC536N-mock cells accumulated in the G2 phase of the cell cycle (Fig 6B) . In contrast, HSC536N-wt FAC cells did not accumulate in G2 to the same extent (Fig 6D) . The reduction of MMC-induced G2 accumulation by wild-type FAC expression was defined as a 100% correction. Transfection with the mock pREP4 vector resulted in a 0% correction.
Transfected HSC536N cells expressing either wild-type or amino terminal truncated FAC polypeptides were next analyzed by this functional assay (Table 2 and Fig 7) . In the absence of MMC, all transfected cell lines had similar cell cycle distributions (Table 2) . Following treatment with MMC for 24 hours, HSC536N-T1 and HSC536N-T2 cells corrected MMC-induced G2 accumulation by 37% and 49%, respectively (Fig 7) . Cells transfected with vector alone, the T3 mutant, or a full-length FAC(L554P) mutant accumulated in G2 phase similar to parental untransfected cells. Taken together, these data are concordant with the cytotoxicity data (Fig 5) and demonstrate that the amino terminus of FAC can be truncated with only partial loss of FAC function. The FAC gene directs the synthesis of the FRP-50 polypeptide by one of two possible mechanisms. First, an alternative splicing mechanism could generate an FAC mRNA that lacks exon 1 sequences. Second, a ribosomal skip mechanism could generate a truncated protein (FRP-50) that initiates at an internal methionine, downstream of methionine 1 (Ml) (Fig 4) . In either mechanism, the region of exon 1 that contains an in-frame STOP codon would be omitted, and a continuous reading frame would be generated that encodes While we cannot rigorously distinguish between these possibilities, our data strongly support the mechanism of internal translation i n i t i a t i~n .~~ First, FRP-50 has the same molecular weight as the T2(M55) polypeptide that is expressed in transfected cells (Fig 4C) or synthesized by in vitro translation (data not shown). Second, increased levels of both FAC and FRP-50 are found in cells transfected with a full length FAC cDNA that contains no intron sequences (Fig 4B, lane 4) . Third, the DNA sequence surrounding codon 55 (AAGAGATGG) -resembles a Kozak consensus sequence (CC~GCCATGG), -particularly at bases -3 and +1, and is, therefore, a plausible site for translation reinitiati~n.'~.'~ Finally, the delG322 mutation in codon 22 (Fig 1) is found upstream of M55, and translation of FRP-50 is not affected by this m~tation.~' In contrast, the IVS4 +4 A to T mutation is downstream of M55 and translation initiation at M55 would not yield a functional FAC isoform. Several mammalian genes have been described that generate protein isoforms by alternative initiation of translation. For instance, internal translation initiation can account for a comparatively mild variant of Duchenne Muscular Dy~trophy.~' In these cases, translation of carboxy terminal polypeptides from downstream start codons account for the milder phenotype.
Primary cells and immortalized cell lines, derived from patients with either delG322 or IVS4 + 4 A to T mutations, exhibit similar sensitivity to MMC in vitro (A. D' Andrea, unpublished results, June 1995). The endogenous low-level expression of FRP-50 in cells with the delG322 mutation, therefore, does not improve their cellular sensitivity to MMC. The partial correction of MMC sensitivity by the T2 mutant observed in the cytoxicity assay (Fig 5) and in the G2 accumulation assay (Fig 7) , may, therefore, result from overexpression of FRP-50 in transfected cell lines. Still, overexpression of other mutant FAC polypeptides such as FAC (T3) (Fig 4) and FAC(L554P)'6.25 fails to even partially correct the MMC sensitivity of the HSC536N cells. Taken together, these
FRP-50.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org Table 2 . Correction with FAC(wt) is defined as a 100% correction results suggest that the endogenous FRPJO levels in cells with delG322 has no effect on cellular MMC sensitivity in vitro, but a measurable protective effect against severe phenotypic features of FA. Other mutations in the FAC gene may account for mild or even subclinical cases of FA. As discussed above, patients with the delG322 mutation frequently have no skeletal abnormalities and develop hematologic disease later.
It is possible that even more subtle mutations in the FAC gene could account for the later onset of aplastic anemia or leukemia. The actual incidence of FA, therefore, may be higher than previously calculated.' Also, because the DEB test is a highly sensitive and specific test,3 the test should be employed for more patients with sporadic onset of aplastic anemia or acute myeloid leukemia.3' even in the absence of congenital abnormalities.
Finally, the cellular function of the FAC polypeptide remains unknown. FA genes have been proposed to play a role in DNA repair,""." cell cycle regulation,'"^*' cellular response to oxidative stress,"' and prevention of apoptoskM As FRPJO has partial functional activity and lacks the amino terminal 54 amino acids, a critical functional domain must exist in the more carboxy portion of the protein. 
